Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Jul;35(7):681-6.
doi: 10.1002/phar.1611. Epub 2015 Jul 3.

Clinical Outcomes in Patients With Parkinson's Disease Treated With a Monoamine Oxidase Type-B Inhibitor: A Cross-Sectional, Cohort Study

Free PMC article
Comparative Study

Clinical Outcomes in Patients With Parkinson's Disease Treated With a Monoamine Oxidase Type-B Inhibitor: A Cross-Sectional, Cohort Study

Khashayar Dashtipour et al. Pharmacotherapy. .
Free PMC article


Study objective: To evaluate the long-term risk of developing cognitive symptoms (e.g., dementia, hallucinations), dyskinesia, falls, and freezing of gait (FoG) in patients with Parkinson's disease (PD) who received monoamine oxidase type B inhibitors (MAOB-Is) compared with patients who had never received MAOB-Is.

Design: Retrospective, cross-sectional, cohort study.

Setting: Academic movement disorders clinic.

Patients: One hundred eighty-one patients with idiopathic PD who were receiving MAOB-I therapy on a long-term basis for a minimum of 1 year (MAOB-I current-user cohort) and 121 patients with idiopathic PD who had never received MAOB-I therapy (MAOB-I never-user cohort [control group]) between January 1, 1996, and November 30, 2011.

Measurements and main results: The five study outcome variables were dementia, dyskinesia, falls, FoG, and hallucinations. Baseline and outcome data were collected from medical records. Patients in the MAOB-I current-user group were included only if absence of the specified outcomes was documented at baseline. Adjusted multiple logistic regression analyses were performed to calculate the odds ratios (ORs) for MAOB-I use versus never use on clinical outcomes. MAOB-I treatment was associated with a 44.7% reduced risk of dyskinesia (adjusted OR 0.553, 95% confidence interval 0.314-0.976, p=0.041), with the greatest risk reduction observed after 2 years of treatment. No significant association was noted with MAOB-I use and development of dementia, falls, FoG, or hallucinations.

Conclusion: Long-term use of MAOB-I therapy was associated with reduced risk of dyskinesia in patients with PD.

Keywords: Parkinson's disease; dyskinesia; monoamine oxidase inhibitor; rasagiline; selegiline.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles


    1. Braak H, Del Tredici K. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 2008;70:1916–25. - PubMed
    1. Shulman LM. Understanding disability in Parkinson's disease. Mov Disord 2010;25(suppl 1):S131–5. - PubMed
    1. Fernandez HH, Chen JJ. Monoamine oxidase‐B inhibition in the treatment of Parkinson's disease. Pharmacotherapy 2007;27(12 Pt 2):174S–85S. - PubMed
    1. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second‐generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 2007;29:1825–49. - PubMed
    1. Katzenschlager R, Head J, Schrag A, et al. Fourteen‐year final report of the randomized PDRG‐UK trial comparing three initial treatments in PD. Neurology 2008;71:474–80. - PubMed

Publication types